{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T17:32:28Z","timestamp":1769103148569,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UK Departments of Health"},{"name":"Wilex AG"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ejca.2016.08.026","type":"journal-article","created":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T11:46:31Z","timestamp":1475149591000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours"],"prefix":"10.1016","volume":"68","author":[{"given":"David","family":"Jamieson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie J.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julieann","family":"Sludden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvette","family":"Drew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Cresti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Swales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Merriman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodger","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bevan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Buerkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Mala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Dean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair","family":"Greystoke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udai","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.R. Jeffery","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Anthoney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Ranson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan V.","family":"Boddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2016.08.026_bib1","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2016.08.026_bib2","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.8052857","article-title":"Transformation of mammalian cells by constitutively active MAP kinase kinase","volume":"265","author":"Mansour","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ejca.2016.08.026_bib3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2004.09.022","article-title":"Guilty as charged: B-RAF is a human oncogene","volume":"6","author":"Garnett","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2016.08.026_bib4","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1158\/1078-0432.CCR-09-0317","article-title":"In\u00a0vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models","volume":"15","author":"Hoeflich","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.08.026_bib5","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"Yeh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.08.026_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2016.08.026_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","article-title":"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study","volume":"14","author":"J\u00e4nne","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2016.08.026_bib8","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2016.08.026_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2016.08.026_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2016.08.026_bib11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2016.08.026_bib12","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2016.08.026_bib13","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.08.026_bib14","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.ejca.2013.01.013","article-title":"A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies","volume":"49","author":"Cohen","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2016.08.026_bib15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2016.08.026_bib16","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1158\/1078-0432.CCR-12-0868","article-title":"Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors","volume":"18","author":"Leijen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.08.026_bib17","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1200\/JCO.2005.14.415","article-title":"Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies","volume":"23","author":"Lorusso","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.08.026_bib18","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-12-0742","article-title":"First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK\/RAF inhibitor in patients with solid tumors","volume":"18","author":"Martinez-Garcia","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.08.026_bib19","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/annonc\/mdt580","article-title":"Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study","volume":"25","author":"Schadendorf","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2016.08.026_bib20","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1158\/1078-0432.CCR-12-3529","article-title":"Multicenter phase I trial of the mitogen-activated protein kinase 1\/2 inhibitor BAY 86-9766 in patients with advanced cancer","volume":"19","author":"Weekes","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.08.026_bib21","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1200\/JCO.2010.33.9473","article-title":"Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers","volume":"29","author":"Bekaii-Saab","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.08.026_bib22","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10637-010-9392-8","article-title":"A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1\/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens","volume":"29","author":"Bennouna","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2016.08.026_bib23","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1097\/JTO.0b013e3181e8b3a3","article-title":"A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens","volume":"5","author":"Hainsworth","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2016.08.026_bib24","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/1078-0432.CCR-09-1920","article-title":"A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer","volume":"16","author":"Haura","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.08.026_bib25","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO.2010.33.9432","article-title":"Phase II study of the mitogen-activated protein kinase 1\/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma","volume":"29","author":"O'Neil","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.08.026_bib26","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-12-3476","article-title":"Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E\/K-mutated melanoma","volume":"19","author":"Catalanotti","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.08.026_bib27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2016.08.026_bib28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1758834015571111","article-title":"MEK and PI3K inhibition in solid tumors: rationale and evidence to date","volume":"7","author":"Jokinen","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2016.08.026_bib29","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/annonc\/mdu054","article-title":"DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma","volume":"25","author":"Gupta","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2016.08.026_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/bjc.2015.215","article-title":"Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer","volume":"113","author":"Janne","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2016.08.026_bib31","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cllc.2015.12.010","volume":"17","author":"J\u00e4nne","year":"2016","journal-title":"Clin Lung Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916323991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916323991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T02:51:19Z","timestamp":1536375079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804916323991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":31,"alternative-id":["S0959804916323991"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.08.026","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}